XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) č. 1062/2014
xx xxx 4. xxxxx 2014,
týkající se xxxxxxxxxx programu xxxxxxxxxxxxxx xxxxxxxx všech xxxxxxxxxxx xxxxxxxx látek xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx, které xxxx uvedeny x xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) č. 528/2012
(Xxxx x xxxxxxxx pro XXX)
XXXXXXXX XXXXXX,
x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,
x ohledem xx xxxxxxxx Evropského parlamentu x Rady (EU) x. 528/2012 xx xxx 22. xxxxxx 2012 x xxxxxxxx xxxxxxxxxx přípravků na xxx x xxxxxx xxxxxxxxx (1), a xxxxxxx xx čl. 89 xxxx. 1 xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx,
xxxxxxxx x těmto důvodům:
|
(1) |
Nařízení Xxxxxx (XX) x. 1451/2007 (2) xxxxxxx xxxxxxxxx pravidla xxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxx účinných xxxxx (dále jen „xxxxxxx xxxxxxxx“), xxxxx xxx zahájen v souladu x xx. 16 odst. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX (3). Xxxxxxx xxxx xxxxxxxx xxxx xxxxxxx x xxxxxxxxx xxxxxxxxx (EU) x. 528/2012, měla xx xxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx ustanovením xxxxxxxxx nařízení. |
|
(2) |
Je xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx a xxxx xxxxxxxxx, xxxxx xxxxx xxx xxxxxxxx xx xxx x xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxx článku 89 xxxxxxxx (XX) x. 528/2012 s výhradou xxxxxxxxxxxxxx předpisů. Xxxx xx xxxx být x x případě xxxxxxxxx xxxxxx xxxxx x xxxx přípravku, xxxxx xxxx xxxxxxxxx x programu xxxxxxxx. |
|
(3) |
Xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxx potraviny x xxxxxx xxxxx xxxxxx 6 xxxxxxxx (XX) x. 1451/2007, xxx nevztahuje xx xx xxx xxxxxxx xxx potraviny x xxxxxx xxxxxxx x xx. 2 xxxx. 5 xxxx. x) xxxxxxxx (XX) x. 528/2012, xxxx xx xxx xxxxxx látky, xxxxx xxxxxxxx, hodnoceny x xxxxxxxx xxxxxxxx xxx xxxxxxxxx xxx přípravku. X xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxx xxxxxxxx xx xxx x xxxxxxxxx umožněno až xx xxxxxxxx xxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx prohlášení xx xxx vymezit, xxxxx xxxxxxxxx xxxxxx xxxxxxxxxx využijí. Xxxxx xx xxxx platit x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx x xxxx přípravku vyplynulo x nové xxxxxxxx xxxx xxxxxxxxx x xxxxxxxx (XX) x. 528/2012 xxxxxx xxxxxxxx xxxxxxx xx xxxxxxxx 98/8/XX nebo xx xxxxx xxxxxxxxxx xxxxxxxxxxx Xxxxxx xxxxxxxx x xxxxxxx x xx. 3 xxxx. 3 xxxxxxxx (EU) x. 528/2012, xxxxxxxxxxx (xxxxxxxxx xxxxxxxxxxx xx xxxx X-420/10 (4)) xxxx xxxxxxxxx pokyny Xxxxxx xx xxxxxxxxxxx xxxxxx xxxxxxxxx států, xxxxx xx xxxxxxxx xxxxxxx. |
|
(4) |
Xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx účinnou xxxxx, xxxxx xxx není xxxxxxxx xx programu xxxxxxxx, x xxxx xxxxx xxxxxxx nebo xx x xx xxxxxx, xxxxx současně xx xxxxxxxxx xxxxxx xxxxxxxxxx přípravku v členském xxxxx xxxxxxxx, xxxx xx xxx x xxxxx xxxxxxxx xxxxx xxxxxxx x xxxxxxxx na trh xxxxxxxx xx jeho xxxxxxxxxxxx, xx xxxxxxxx xxxxxxxx x xx xxxxxxxx xxxx. |
|
(5) |
X zájmu jednotnosti x xxxxxxxxxxxx by xxx xxx xxxxxx xxxxxxxxx xxxxxxxx látek x xxxxxxxx xxxxxxxx xx všech xxxxxxxxxx xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) x. 528/2012 xxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (EU) x. 88/2014 (5). |
|
(6) |
Xxx xxxxx, které splňují xxxxxxxx xxxxxxxxx nebo xxxxxxxx xxx náhradu, xx xxx hodnotící xxxxxxxxx orgán xxxxxxxxx xxxxxxxx návrh harmonizované xxxxxxxxxxx a označení látky xxxxx čl. 37 odst. 1 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 (6), xxxxx xxx x xxxxxxxxx vlastnosti vzbuzující xxxxx, x xxxxxxx by xxxx xxx xxxxxxxxx xxxxx xxxxxxxxx státu xxxxxxxxx xxxxx týkající xx jiných xxxx xxxxx xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx příslušný orgán xx xxx také xxxxxxxxxxx xxxxxxxx x xxxxxxx látek, xxxxx xx splňovaly kritéria xxx látky xxxxxxxxxxxx, xxxxxxxxxxxxxxx xx xxxxxxx, xxxx xxxxx, které xx xxxxx xxx xxxxxxxxxx xx xxxxx s vlastnostmi xxxxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx. |
|
(7) |
Xxx bylo zajištěno, xx xxxxxxx xxxxxxxx xxxx xxxxxxxx xx xxxxxxxx xxxx xxxxxxxxx x xx. 89 odst. 1 xxxxxxxx (XX) č. 528/2012, xxxx xx xx xxxxxxxxx xxxxxx na xxxxxxxxx xxxxxx xxxxx a typu xxxxxxxxx, x xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxx stanovených x xxxxxxxx (ES) č. 1451/2007 xxxx x xxxxx xxxxxxxx. Xxxxx xxxx xx xx měly xxxxxxxx xxxxxx xxxxx pro xxxxxxxxx xxxxxxxxx, přičemž xx xx xxxx xxxx v úvahu xxxxxxx, xx xxxxxxx xx xxxxx xxx xxxxxxxxx xxxx xxx xxx před xxxxxxxxx xxxxxx xxxx. |
|
(8) |
Ohledně xxxxxxxx xx xxxxxxx X xxxxxxxxx 7 xxxxxxxx (XX) x. 528/2012 xxxxx xxxxxx stanoveny žádné xxxxxxxxx na xxxxx. Xx xxxxx vhodné x xxxx xxxx xxxxxx xxxxxxx o zařazení xx xxxxxxx xxxxxxx xx kategorie 1, 2, 3, 4, 5 xxxx 6. |
|
(9) |
Bez xxxxxx xx xx. 90 odst. 2 xxxxxxxx (EU) x. 528/2012 xxxxxxx x xxxxxx 91 xxxxxxxxx nařízení, že xxxxxxxx uvedená v článku 10 xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxx xxx xxxxxxxx povolování xxxxxxxxxx přípravků ve všech xxxxxxxxx. Xx xxxxx xxxxxx xxxxx xxxxx xxxxxxxxx xxxx xxxxxxxx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx. |
|
(10) |
Xxxxxxxxxxx xxxxxxxx programu xxxxxxxx xx měl xxx xxxxxxx se xx xxxxxxxx dohodě xxxxxxxx xx stávajícímu xxxxxxxxxxx xxxx jej xxxxxxxx za xxxxxxxxxxx, xx xxxxx xxxx xxxxxxx ke xxxxxxxx xxxxxxxxx x xxxxxx xxxxxxxxx xxxxxxxx k xxxxxx, xxxxxxx xxxxx xx xxxxxxxxxxx xxxxxxxx musel xxxxxxxxx xxxxx xxxxx. |
|
(11) |
Protože xx xxxxx v programu xxxxxxxx xxxxxxxxxx, mělo xx být xxxxxxxxxx xxxxxxxx od xx xxxxxxxxx. Xxxxx x xxxx xxxxx, xxxx xx xxx xxxxxxxxxxx xxxxxxxxx možnost xxxxxxx xxxxxxx, xxxxxx-xx xxxx xxxxxxxx xxxxxxx xxx xxxxxx, neboť xxx xxxxxxx xx xxxxxxxx xxxxxxxx xxxxxxxx, a xxxxxxxx-xx agentura xxx xxxxxxxx xx xxxx xxxxxxxxxx. |
|
(12) |
Xxxxx xx xxx xxxxxxxxx xxxxxx látky xxxxx, xx xxxxxxxx xxxxxxxxx xxxxxxxx do programu xxxxxxxx xxxxxx neodpovídá identitě xxxxxxxx hodnocené látky, x x hodnocení xxxxx xxxxxxx xxxxxx ohledně xxxxxxxx oficiálně xxxxxxxx xxxxx, mělo xx xxx xxxxx xxxx xxxxx x xxxxxxx hodnocení xxxxx definovat x xxxxxxx xxxxx xxxxxx, xxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx látky. |
|
(13) |
Některé xxxxx zařazené xx xxxxxxxx xxxxxxxx xxxxxx x xxxx xxxxxxx xxxxxx nařízení podporovány xxxxxx xxxxxxxxxx. Xxxxx xx xxxx xxxxxxxx xxxxxxxxxxxxx, xxxxxx xxxxx xx. 4 odst. 4 xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxx není xxxxxxxx stanoveno. X xxxxxxxxx xxxxx a xxxxxxxxxxxxx xx xxxx xxx osoby možnost xxxxxxx xxxxx, protože xxxxx xx xxxx xxxxx a nanomateriály xxxxxx xxx x xxxxxxxx xxxxxxxx xxxxxxxxx. |
|
(14) |
Xxx bylo xxxxxxxxx, xx xxxxx xxxxx nezůstane x xxxxxxxx neoprávněně xxx xx xxx nebude xxxxxxxx, xxxx xx xxxxxxxx byla xxxxxxxxxxx, xxxx by xxxxxxxx xxxxx, xxxxx xxxxx xxxxxx hodnocena, v xxxxxxxx nebo xxxx xxxxxxxx podléhat oznamování xxxxxxxxxx xxxxx x xx, |
XXXXXXX XXXX XXXXXXXX:
XXXXXXXX 1
XXXXXXX X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxx pracovního programu xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx účinných xxxxx xxxxxxxxx v článku 89 nařízení (XX) x.&xxxx;528/2012.
Xxxxxx 2
Definice
Xxx účely xxxxxx xxxxxxxx xx xxxxxxx xxxx definice:
|
a) |
„xxxxxxxxxxx x xxxxxxxxxxx“ xx xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxx xx. 9 xxxx. 1 xxxx. x) nařízení (XX) č. 528/2012 nebo xx. 89 odst. 1 xxxxxxx xxxxxxxxxxx uvedeného xxxxxxxx, xxxx xxxxxxxxx xxxxxxxxx xx xxxxxxx X xxxx IA xxxxxxxx 98/8/XX; |
|
b) |
„xxxxxxxxx xxxxx x xxxx xxxxxxxxx zařazenou xx xxxxxxxx xxxxxxxx“ se xxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxx x xxxxxxx II, xxxxx xxxxxxx xxxx podmínky:
|
|
c) |
„xxxxxxxxxx“ xx xxxxxx xxxxx, xxxxx xxxxxxxxxx žádost x xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxx do programu xxxxxxxx xxxx xxxxxxxxxx xxxxxxxx, xxxxx odpovídá xxxxxxxxxx podle čl. 17 xxxx. 5 tohoto nařízení, xxxx xxxxxx xxxxxx xxxx xxxx žádost xxxx oznámení xxxxxxxxxx; |
|
x) |
„xxxxxxxxxx xxxxxxxxxx xxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx uvedeného x příloze XX xxxxxx xxxxxxxx, xxxxxx x xxxxxxx s článkem 81 nařízení (XX) č. 528/2012. |
KAPITOLA 2
XXXXXX HODNOCENÍ XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxx I xxxxxxxx (EU) x. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx o schválení xx xxxxxxxx do přílohy I nařízení (XX) č. 528/2012 může xxxxx xxxxx účastník, x xxxxx oznámení xxxxx agentura x xxxxxx, xx xxxxxxxx xxxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5 tohoto nařízení.
Pokud xx xxxxxx týká xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012, xxxx xx týkat xxxxx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 uvedené xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx uvedené v odstavci 1 xx xxxxxxxx xxxxxxxx do dvou let xx xxxxxxxxxx x&xxxx;xxxxxxx x xxxxxxxxx xxxxx xx.&xxxx;17 odst. 5.
Xxxxxx 4
Xxxxxxx žádostí
1. Xxxxxxxx xxxxxxxxx účastníka x xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx nařízení Xxxxxx (XX) č. 564/2013 (7) x zamítne žádost, xxxxx účastník xxxxxxxxx xxxxxxxx xx xxxxx 30 xxx. X xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx.
2. Xx xxxxxxxx xxxxxxxx splatných podle xxxxxxxxxxx nařízení (EU) x. 564/2013 přijme xxxxxxxx xxxxxx x xxxxxxxxx x xxx xxxxxxxxx x xxxxxxxxx příslušný xxxxx, xxxxxxx xxxxx datum xxxxxxx žádosti x xxxx xxxxxxxxx identifikační kód.
3. Xxxxx xxxxxxxxxxx agentury xxxxx xxxxxxxx 1 xxxxxx xxxxxx xxx xxxxx xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 77 xxxxxxxx (XX) x. 528/2012.
4. Hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx x poplatku xxxxxxxx xxxxx čl. 80 xxxx. 2 nařízení (XX) x. 528/2012 xx 30 xxx xxxx, xx agentura xxxxxxx xxxxxx, x xxxxxxx xxxxxx, xxxxx xxxxxxxx nezaplatí xxxxxxxx xx xxxxx 30 xxx. X xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx.
Xxxxxx 5
Xxxxxxxxx žádostí x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxxxx 6 přílohy I xxxxxxxx (XX) č. 528/2012
1. Xxxxx xxxxxxxx xxxxxx xxxxx čl. 4 xxxx. 2 žádost x xxxxxxxxx nebo zařazení xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (XX) č. 528/2012, xxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxx s čl. 6 xxxx. 1 x 2 xxxxxxxxx xxxxxxxx, a byl xxxxxxxx xxxxxxxx xxxxx xx. 4 xxxx. 4, xxxxxxxxx xxxxxxxxx orgán žádost xxxxxxx do 30 xxx xx zaplacení xxxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx dokumentaci xxxxx xxxxxxxx (ES) x. 1451/2007, xxxxx xx xxxxx xxxxxx xxxxxx xxxx xxxxx xxxxx xxxxxx 13 uvedeného xxxxxxxx, potvrdí xxxxxxxxx xxxxxxxxx orgán xxxxxx xxxxxxxxxx xx 3. xxxxx 2015.
3. X xxxxxxxxx xxxxxxxxx x xxxxxxxxxx 1 x 2 hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxx předložených xxxxx xxxx odůvodnění.
4. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxx, xx xxxxxx je xxxxxxx, sdělí účastníkovi, xxxx xxxxxxxxxx xxxxxxxxx xxxx x potvrzení xxxxxxx xxxxx, x x předložení těchto xxxxxxxxx xxxxxxx přiměřenou xxxxx. Xxxx xxxxx xxxxx xxxxxxxxxx 90 xxx.
Xxxxxxxx-xx xxxxxxxxx příslušný xxxxx, xx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx ke xxxxxxx požadavků xxxxxxxxx x xxxxxxxx 2, xxxxxxx xxxxxx xx 30 xxx xx xxxxxxxx doplňujících xxxxxxxxx.
Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxx x informuje x xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxx. X xxxxxx xxxxxxxxx se xxxxx xxxxxxxx zaplacené x xxxxxxx x xx. 80 xxxx. 1 x 2 nařízení (XX) x. 528/2012.
Xxx potvrzení žádosti xxxxxxxxx xxxxxxxxx orgán xxxxxxxxxx informuje účastníka, xxxxxxxx x xxxxx xxxxxxxxx xxxxxx a uvede xxxxx xxxxxx potvrzení.
Xxxxxx 6
Xxxxxxxxx žádostí
1. Xxxxx xxxxxx xx použije, xxxxx xxxxx některá x xxxxxx podmínek:
|
x) |
xx-xx žádost xxxxxxxxx podle článku 5; |
|
x) |
xxxxx hodnotící xxxxxxxxx xxxxx xxxxx xxxxxxxxxxx xxxx úplnou xxxxx xxxxxx 13 xxxxxxxx (XX) x. 1451/2007, ale xxxxx xxxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx orgánu xxxxx xx. 14 odst. 4 uvedeného xxxxxxxx; |
|
x) |
xxxxx xxxxxxxx přijala xxxxxx x zařazení xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 xxxxxxx X xxxxxxxx (XX) č. 528/2012 xxxxx xx. 4 odst. 2 x xxx xxxxxxxx xxxxxxxx xxxxx čl. 4 odst. 4. |
2. Hodnotící xxxxxxxxx xxxxx xxxxxxxx xxxxxx xxxxx xxxxxx 4 x 5 xxxxxxxx (XX) x. 528/2012 x xxxxxxxx xxx xxxxxxx xxxxxx xx úpravu požadavků xx xxxxx předložené x souladu x xx. 6 odst. 3 xxxxxxxxx xxxxxxxx x xxxxx hodnotící xxxxxx x xxxxxx xxxxx xxxxxxxxx agentuře.
3. Xxxxx xxxxxxx kombinaci xxxxx x typu xxxxxxxxx xxxxxxxxx několik xxxxxxxxx, xxxxxxxxx hodnotící xxxxxxxxx xxxxx xxxxx jednu xxxxxxxxx zprávu. Xxxxxxxxx xxxxxx x xxxxxx xxxxx x xxxxx x xxxxxx xxxx, podle xxxx, xx xxxxxxx xxxxxxx:
|
x) |
365 xxx xx xxxxxxxxx xxxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x), xxxxxx xxxxxxxx xxxxxxxx v odst. 1 xxxx. x) xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx x xxxx. 1 xxxx. x) x dotyčné xxxxxxxxx xxxxx x xxxx xxxxxxxxx; |
|
b) |
ve xxxxx stanovené v příloze XXX. |
4. Xxxx xxx, xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxx závěry xxxxxxxx, xxxxxx účastníkovi xxxxx xx 30 xxx x xxxxxxxxx xxxxxx x k xxxxxxx xxxxxxxxx písemné xxxxxxxxxx. Hodnotící xxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx způsobem xxxxxxxx x závěrečné xxxx xxxxx xxxxxxxxx.
5. Pokud xx xxxxx, xx xxxx x xxxxxxxxx nutné xxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx účastníka xxxxx, xxx xxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxx, a xxxxxxxxx o tom xxxxxxxx.
Xxxxx 365 xxx xxxxxxx x xxxxxxxx 3 xx xxxxxxx xx dobu xxx xxx vznesení xxxxxxxxx xx dne xxxxxxxx xxxxxxxxx. Xxxxx to xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx údajů xxxx xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx:
|
x) |
365 xxx x xxxxxxx, xx xx doplňující informace xxxxxx xxxxxx, xxxxx xxxxxx řešeny x xxxxx směrnice 98/8/XX xxxx v rámci xxxxxxx xxxxxxxxxxx xxx uplatňování xxxxxxx xxxxxxxx; |
|
x) |
180 xxx xx xxxxx xxxxxxxxx případech. |
6. Pokud xxxxxxxxx xxxxxxxxx xxxxx xxxxxx, xx xxxxxxxx xxxxx ohledně zdraví xxxx nebo zvířat xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx biocidních xxxxxxxxx xxxxxxxxxxxx stejné xxxx xxxxxxxx xxxxxx xxxxx, xxx xxxxx xxxxxxxxxxxx x xxxxxxx x xxxxxxxxx příslušných xxxxx xxxxxx XX xxxx 3 xxxxxxx XX nařízení Evropského xxxxxxxxxx x Rady (XX) x. 1907/2006 (8) a zahrne xx xx svých xxxxxx.
7. X xxxxxxx xxxxxxx xx xxxxxxxxx hodnocení xxxxxxxxxxxxx hodnotící příslušný xxxxx xxx xxxxxxxxxx xxxxxxx a nejpozději při xxxxxxxxxx xxxxxxxxx zprávy xxxxx xxxxxxxx 3:
|
x) |
xxxxxxxx xxxxx xxxxxxxx xxxxx xx. 37 xxxx. 1 xxxxxxxx (XX) č. 1272/2008, jestliže xx xxxxxxx, xx xx xxxxxxx xxxxx z kritérií xxxxxxxxx x xx. 36 odst. 1 xxxxxxxxx xxxxxxxx, xxx xxxx náležitě řešeno x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
|
x) |
xxxxxxxxxx x xxxxxxxxx, xxxxx se xxxxxxx, xx xxxxx x xxxxxxxx xx. 5 xxxx. 1 xxxx. x) xxxx x) xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxx xx. 10 odst. 1 xxxx. x) xxxxxxxxx xxxxxxxx xxxx xxxxxxx, xxx xxxxxx xxxxxxxx xxxxxx x xxxxxxx XXX nařízení (XX) x. 1907/2006 nebo x xxxxxxx xxxxxxxx x xx. 59 odst. 1 xxxxxxxxx xxxxxxxx. |
Xxxxxx 7
Stanovisko xxxxxxxx
1. Tento xxxxxx xx použije, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
|
x) |
pokud hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xx. 6 odst. 2 a xxxxxxxx xxxxxxxxx xxxxx xxxx provedl konzultaci xxxxx čl. 6 odst. 7; |
|
x) |
xxxxx xxxx xxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxx xx. 14 xxxx. 4 xxxxxxxx (XX) x. 1451/2007, xxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxx Xxxxx xxxxx pro biocidní xxxxxxxxx podle xx. 15 xxxx. 4 xxxxxxxxx xxxxxxxx. |
2. Xx xxxxxxx xxxxxx agentura xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx o schválení xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxx xxxx xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxxxxx xxxxxx, x xxxxxxx xx xxxxxx hodnotícího příslušného xxxxxx.
Xxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx x xxxxx z těchto xxxx, podle xxxx, xx nastane později:
|
x) |
xx xxx měsíců xx xxxxxxx xxxxxx; |
|
b) |
xx lhůtě xxxxxxxxx x xxxxxxx XXX. |
Agentura xxxxxxxx xxxxxxxxxx Xxxxxx xx 270 xxx od zahájení xxxxxxxx.
Xxxxxx 8
Účinné xxxxx, xxxxx xx mají xxxxxxxx
1. Xxx přípravě xxxxx xxxxxxxxxx xxxxx xx. 7 xxxx. 2 agentura xxxxxxx, xxx účinná látka xxxxxxx xxxxxxx z kritérií xxxxxxxxx v čl. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, x xxxx otázku xxxxx xx xxxx xxxxxxxxxx.
2. Aniž xxxx xxxxxxx xxxxxx 66 x 67 nařízení (EU) x. 528/2012, dříve xxx xxxxxxxx předloží xxx xxxxxxxxxx Xxxxxx, xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxx, xxxxx xx xxxx xxxxxxxx, během xxxxxxxxx 60 xxx; v xxxx době mohou xxxxxxxxxx xxxxx strany xxxxxxxxx xxxxxxxxx informace xxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx. Agentura xxxxxxxx xxxxxxxxx xxxxxxxx zohlední x xxxxxxxxx xxxx xxxxxxxx xxxxx stanoviska.
3. Pokud xx xxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxx x xxxxxxxx stanovených x xx. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xxxx xxx xxxxxxxx xx xxxxx, xxxxx xx má xxxxxxxx, x xxxxxxxx přijatém x xxxxxxx x xx. 89 xxxx. 1 xxxxxx xxxxxxxxxxxx uvedeného xxxxxxxx.
Xxxxxx 9
Xxxxxxxxxx Xxxxxx
Xx xxxxxxxx stanoviska agentury xxxxx čl. 7 odst. 2 Xxxxxx xxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx xxx přijetí xxxxx čl. 89 xxxx. 1, xxxx případně podle xx. 28 xxxx. 1 xxxxxxxx (XX) x. 528/2012.
XXXXXXXX 3
XXXXX XXXXX XXXXXXXX XXXXXXXX
Xxxxxx 10
Xxxxxxxxx xxxx xxxxxxxxx účastníků xx xxxxxxxx xxxxxx
1.&xxxx;&xxxx;&xxxx;Xxxx xxxxxxxxx je možno xx xxxxxxxx xxxxxx xxxx stávajícím účastníkem x xxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xx xxxxxxxxxxx, že xx potenciální účastník xxxxx odvolávat xx xx xxxxxxx údaje xxxxxxxxxx xxxx uvedené xxxxxxxxxx xxxxxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxxx pro xxxxx xxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx společně xxxxxxxxxxx a stávající xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx pro xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxx 71 xxxxxxxx (XX) x. 528/2012 (dále jen „xxxxxxxx“) x&xxxx;xxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxx k přístupu.
3. Po xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx podle odstavce 2 xxxxxxxx aktualizuje xxxxxxxxx v rejstříku xxxxxxxx xx totožnosti xxxxxxxxx.
4.&xxxx;&xxxx;&xxxx;Xxxxx xxxxxxx xx&xxxx;xxxxx Xxxx, xxxxx převzala xxxx xxxxxxxxx nebo xx xxxxxxxxx k xxxxxxxxxxx xxxxx tohoto xxxxxx, xx xxx účely xxxxxx 95 nařízení (XX) x.&xxxx;528/2012 xxxxxxxxxx xx osobu, xxxxx xxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Xxxxxxxxxx účastníků
1. Má xx xx xx, xx xxxxxxxx xxxxxxxxx x xxxxxx na xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxxxxx xxxxxxxx, x těchto xxxxxxxxx:
|
x) |
xxxxx xxxxxxxxxx agenturu xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x svém xxxxxx xxxxxxxxx; |
|
x) |
xxxxx xxxxxxxxxxx xxxxxx xx xxxxx xxxxxxx x xx. 3 xxxx. 2; |
|
c) |
pokud jeho xxxxxx xxxx xxxxxxxxx xxxxx xx. 4 xxxx. 1, xx. 4 xxxx. 4 xxxx xx. 5 xxxx. 4; |
|
x) |
pokud xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxx v čl. 6 xxxx. 5; |
|
x) |
xxxxx xxxxx xxxxxxxxxx xxxxxxxx hodnotícímu xxxxxxxxxxx xxxxxx xxxx xxxxxxxx. |
2. Odstoupení xx xxxxxxxx xx xxxxxxxxx xxxx, xxxxx x xxxx xxxxxxx xx datu, kdy xxxxxxxxx příslušný xxxxx xxxxxxxxx xxxxxxxx zprávu xxxxxxxxxxx orgánu xxxxx xx. 6 odst. 4 tohoto xxxxxxxx.
Xxxxxx 12
Důsledky včasného xxxxxxxxxx
1. Xxxxx xx x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx příslušný xxxxx, xxx xxxxxx xxxxxxxx, xxxxxxxxx xx hodnotící xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx je o xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx se xxxxxxxxxx xxxxxxxxx.
3. Pokud z xxxxxxxx přezkumu xxxx xxxxxxxxxx všichni xxxxxxxxx xxxxxxxxxxx xxxxx kombinaci xxxxx a typu xxxxxxxxx x xxxxx xxxx xxxx xxxxxxxxx pro xxxxxxxx xxxxxxxxx xxxxx xxxxxxxx, xxxxxxxxx o tom xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx Xxxxxx.
Xxxxxx 13
Nová definice xxxxxxxxx látek
1. Pokud xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx závěry xxxxxxxx xx xxxxx, xxx xxxx uvedeny x xxxxxxx XX, xxxxxxxxx příslušný xxxxx xx konzultaci x xxxxxxxx účastníkem xxxxxxx xxxxx identitu xxxxx. Xxxxxxxxx xxxxxxxxx xxxxx o tom xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx x xxxxxxxxx aktualizuje xxxxxxxxx týkající xx xxxxxxxx xxxxx.
Xxxxxx 14
Převzetí xxxx xxxxxxxxx
1. Xxxxxxxx xxxxxxxx otevřenou xxxxx x převzetí xxxx xxxxxxxxx xxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxxxx nastane xxxxx x xxxxxx případů:
|
x) |
xxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx včas xxxxxxxxxx xxxxx xxxxxx 11 x xxxxxx role xxxxxxxxx xxx xxxxx kombinaci xxxxxx xxxxxxx převzata; |
|
x) |
na základě xxxx definice xxxxx xxxxxx 13; x xxxxx xxxxxxx xx výzva týká xxxxx xx látky, xx xxxxxx se xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX, xxx nikoliv xxxx xxxxxxxx xxxxx. |
2. Xx xxxxxxxx xxxxxx xxx xxx xxxxxxxxxx xxxxx xxxxxxxx 1 xxxx kterákoli xxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxx článku 17.
3. Xx xxxxxxxx měsíců xx xxxx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxxx do části 2 přílohy II podle xxxxxx 17.
Xxxxxx 15
Xxxxxxxxx látky x typu xxxxxxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx
Pokud xxxxxxxx xxxxxxxxx, který xxxxx xx oblasti xxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xx xxxxxx xx xxx, xxxxxxx xx xxxxxxxxx xxxxxx látky, xxx xxxx xxxxxxxxx xxx xxxxxxxx xx programu xxxxxxxx xxx xxxxx xxx xxxxxxxxx x xxxx zařazena do xxxxxxx X uvedeného xxxxxxxx, tuto xxxxx xxxxxxxx nebo xx x ní xxxxxx, xx uvedená xxxxx xxxxxxxxx pro zařazení xx xxxxxxxx přezkumu xxx xxxxxxxxx typ xxxxxxxxx xx xxxxxxx xxxxxxxxx z těchto xxxxxx:
|
x) |
xxxxx xxxxxxxxx xxxxxxx xx xxx se spoléhala xx xxxxxx nebo xxxxxxx doporučení xxxxxx Xxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 26 xxxxxxxx 98/8/XX xxxx článkem 81 xxxxxxxx (XX) č. 528/2012, xxxxx xx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx důvodů xxxxx xxxxxxx pokyny xx xxxxxxxxxx x xxxxxxxxxxx, že výrobek xxx xxxxx x xxxxxxxxxx xxxxxxxx 98/8/XX xxxx nařízení (XX) x. 528/2012, nebo xx xxx xxxxxxxxx xxx xxxxxxxxx jedním x přípravků, xxx xxxxx byla xxxxxx xxxxx xxxxxxxx, a xxxxx xxxx uvedené xxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx xxxxxxxx podle xx. 3 xxxx. 3 xxxxxxxx (XX) č. 528/2012 xxxx v nových, závazných xxxxxxxx xxxxxxxxxxxx Xxxxxx; |
|
x) |
látka xxxxxxxxx xxxxxxxx xxx xxxxxxxxx x xxxxxx xxxxxxxxx x xxxxxx 6 xxxxxxxx (XX) x. 1451/2007; |
|
x) |
biocidní xxxxxxxxx xxxxx xxxxx nařízení (XX) č. 528/2012 x xxxxxxxxx xxxx xxxxxxxxx, xxx xxxx xxxx xxxxx směrnice 98/8/ES, v důsledku xxxxx xxxxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxxx xxxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx xxx xxxxxxx xxx xxxxxxxxx, xxx xxxxxx pro xxxx. |
Xxxxxx 16
Prohlášení o xxxxx na xxxxxxxx
1. Xxxxxxxxxx x xxxxx oznámit látku, xxxxx je způsobilá xxx xxxxxxxx xx xxxxxxxx xxxxxxxx podle xxxxxx 15, xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx osoba, xxx xx zájem xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxxxxxx x xxxxxxxxxxxxx xxxxxxxx:
|
x) |
Xxxxxx xxxxxxxxxx xxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
|
b) |
xxxxxxxx xxxxxxxxxx 30. xxxxx 2015 x případech uvedených x čl. 15 xxxx. x); |
|
x) |
Xxxxxx xxxxxxxxxx 30. října 2015 x xxxxxxxxx xxxxxxxxx v xx. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxx kombinaci xxxxx x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx v čl. 15 písm. x) xxxx prohlášení xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx, x xxxx xxxxxxx, xx xxxx xxxxxxx xxxxxxx xxxxxxxx v xxx uvedené.
3. Pokud xxxx xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx v čl. 15 xxxx. x) xxxx x) x Xxxxxx xxxxxxx xx xxxxxxxxxx s členskými xxxxx x xxxxxx, že xxxxxxxx 6 xxxx xxxxxxxxxx, x xxxxxxxx, xx xxxx splněny xxxxxxxx xxx xxxxxxxx uvedené x xx. 15 písm. x), xxxxxxx x xxx xxxxxxxx.
4. Xxxxx bylo prohlášení xxxxxxx x xxxxxxx uvedeném x xx. 15 xxxx. x) xxxx xxxxx Xxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 3, xxxxxxxx xxxxxxxx xxxx xxxxxxxxx elektronickými xxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx látky a typu xxxxxxxxx. Xxx účely xxxxxx nařízení se xxxxxxxxxx xxxxx xx. 3x xxxx. 3 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 1451/2007 xxxxxxxx xx zveřejnění xxxxx xxxxxx xxxxxxxx.
5. Xxxxxxxxx xxxxx, která má xxxxx xxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx, xxx xxxx xxxxxx xxxxx xxxxxx 17 xx xxxxx xxxxxx xxx dne zveřejnění xxxxx xxxxxxxx 4.
6. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) a c) xx xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxx x xxxx xxxxxxxxx x dalšímu xxxxxxxx, xxxxx xxxx xxxxxxx xxxx xxxxxxxx:
|
x) |
xxxxxxxxx xxxxxx látka xx xxx zařazena xx xxxxxxxx xxxxxxxx; |
|
x) |
xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx pro xxxxxxxxxx xxxxxxx látku xxx obsahuje všechny xxxxx, xxxxx jsou xxxxxxxx xxx hodnocení xxxx přípravku; |
|
x) |
xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx, že xx xxxxx x xxxxxxx xxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. |
Xxxxxx 17
Postup xxxxxxxx
1. Xxxxxxxx xxxxx čl. 14 xxxx. 2 x 3 xxxx xx. 16 xxxx. 5 xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx xx xxxxxxx XXXXXX. Musí xxxxxxxxx xxxxx uvedené v xxxxxxx X.
3. Pokud není x xxxxxxx XX xxx xxxxxxxx xxxxxxx látku xxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxxx xxx vybraného xxxxxxxxxxx orgánu, xxxxx xx xxxxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (EU) x. 528/2012, x xxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx, xx xxxxxxxxx xxxxx xxxxxxxx x xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx xxxxxxxx xxxxxxxx x xxx uvědomí xxxxxxxx Xxxxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx (XX) x. 564/2013. Xxxxxxxx xxxxxxxxxxx neuhradí poplatky xx 30 xxx xx xxxxxxx xxxxxxx xxxxxxxxx, agentura oznámení xxxxxxx x xxxxxxx x tom xxxxxxxxxxxx x Xxxxxx.
5. Xx uhrazení xxxxxxxx xxxxxxxx do 30 dnů xxxxx, xxx xxxxxxxx vyhovuje xxxxxxxxxx xxxxxxxx v xxxxxxxx 2. Xxxxx xxxxxxxx těmto xxxxxxxxxx xxxxxxxxxx, poskytne agentura xxxxxxxxxxxx lhůtu x xxxxx 30 dnů, xxx své xxxxxxxx xxxxxxx xxxx xxxxxxx. Xx xxxxxxxx xxxx 30xxxxx xxxxx agentura xx 30 xxx xxx xxxxxxxx, xx xxxxxxxx xxxxxxxx požadavkům xxxxxxxx 2, nebo xxxxxxxx xxxxxxx, x xxx xxxxxxxxxx xxxxx xxxxxxxxxxxx a Komisi.
6. X xxxxxxx x xxxxxxx 77 nařízení (EU) x. 528/2012 xxxxx xxxxxxxxxxx agentury xxxxx xxxxxxxx 4 xxxx 5 xxxxx xxxxxxx xxxxxxxxxx.
7. Xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx 5:
|
x) |
x xxxxxxx, xx xxxx xxxxxxxx předloženo xxxxx xx. 14 odst. 2 xxxx 3, agentura xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx a xxxxxxxx xxxxxxxx látky; |
|
x) |
x xxxxxxx, xx xxxxxxxx xxxx xxxxxxxxxx xxxxx čl. 16 xxxx. 5, xxxxxxxx xxxxxxxxxx xxxxxxxxx Komisi, že xxxxxxxxxx bylo xxxxxxxx. |
Xxxxxx 18
Zařazení do xxxxxxxx xxxxxxxx
Xxxxx je xxxxxxxxx látky x xxxx xxxxxxxxx považována xx xxxxxxxxx x xxxxxxx x xx. 16 xxxx. 6 nebo pokud xxxxxxxx xxxxxxxxx Komisi x xxxxxxxx požadavků x xxxxxxx x xx. 17 xxxx. 7 xxxx. x), zařadí Xxxxxx kombinaci xxxxx x xxxx přípravku do xxxxxxxx xxxxxxxx.
Xxxxxx 19
Xxxxxxxxx x xxxxxxx, xxxxx nejsou xxxxxx xxxxxxxxxxx v xxxxx xxxxxxxx přezkumu
Pokud xxxxxx xx xxxxx stanovené x xx. 16 odst. 5 xxxxxxxx xxxxx oznámení xxxx xxxxx xxxx xxxxxxxx xxxxxxx ve zmíněném xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx podle xx. 17 xxxx. 4 xxxx 5, xxxxxxxx x xxx xxxxxxxxx členské státy xxxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxx xxxxxxxxx elektronickou xxxxxx.
Xxxxxx 20
Xxxxxxxxxx Komise x xxxxxxx, xxxxx xxxxxx nadále xxxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxx
Xxxxxx xxxxxxxx xxxxx xxxxxxxxxx x neschválení xxxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxx informuje Xxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxx podle xx. 12 xxxx. 3 tohoto xxxxxxxx; |
|
x) |
xxxxx xxxxx osoba nepodala xxxxxxxx ve lhůtách xxxxxxxxxxx x xx. 14 xxxx. 2 nebo 3 tohoto nařízení xxxx xxxxx bylo xxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxx čl. 17 odst. 4 xxxx 5; |
|
x) |
pokud bylo xxxxxxxx xxxxxxxxxx ve lhůtě xxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx a byly xxxxxxxx xxxxxxxxx xxxxx čl. 17 xxxx. 5 tohoto nařízení, xxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx pouze xxxx stávající xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx. |
X xxxxxxx xxxxxxxx x xxxxxx xxxxxxxxxxx xxxx. x) se xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xx xxxxxx xxxxx, xx xxxxxx xx xxxxxxxx stávající xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxx xxxxxx xxxxxxxx nebo jakékoli xxxxxxxxxx o xxxxxxxxx.
XXXXXXXX 4
PŘECHODNÁ XXXXXXXX
Xxxxxx 21
Xxxxxxxxx opatření pro xxxxx xxxxxxx x&xxxx;xxxxxx&xxxx;15
1.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx svého xxxxxxxxxxx xxxxxxx xxxx praxe xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, který xxxxxxx xx stávající xxxxxx xxxxx uvedené x xx. 15 xxxx. x) x x), xxxx xxxxx xxxxxxxx xxxx x xx xxxxxx. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx nadále xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xxxx vstupu tohoto xxxxxxxx x&xxxx;xxxxxxxx; |
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx mohou xxx xxxx xxxxxxxxx xx&xxxx;30 měsíců po xxx xxxxxx xxxxxx xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx pokračovat x&xxxx;xxxxxxxxxxx xxxxx stávajícího systému xxxx xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx biocidního xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx xxxxx xxxxxxx x xx. 15 xxxx. x), xxxx xxxxx xxxxxxxx nebo x xx vzniká. X xxxxxx případech:
|
a) |
nesmí xxx xxxxxxxx přípravek nadále xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx po xx z xxxx xxxxxxxxx xxxxxxxx, která xxxxxxx později:
|
|
x) |
xxxxxxxxx xxxxxx biocidního přípravku xxxxx xxx xxxx xxxxxxxxx do 30 xxxxxx xx té x xxxx xxxxxxxxx xxxxxxxx, xxxxx xxxxxxx xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx může xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx nebo xxxxx dodávání xx&xxxx;xxx x&xxxx;xxxxxxxxx biocidního xxxxxxxxx, xxxxx xxxxxxx ze xxxxxxxxx xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 xxxx. 4 xxx xxxxxxxxx xxx xxxxxxx, xxxx xxxxx obsahuje xxxx x xx xxxxxx. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx xxxxxx dodáván xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx datu, xxx xxxxxxxx provedla xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxx 19 x |
|
x) |
xxxxxxxxx zásoby xxxxxxxxxx xxxxxxxxx mohou xxx xxxx xxxxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx xxxx xxxxxxxxx xxxxxxxxxx. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Xxxx xx xxxxxx xx. 55 xxxx. 1 xxxxxxxx (EU) x. 528/2012, xx xxxxxxxx xxxxxx xx xxxx xxxxxxxxxx o neschválení xxxxxxxxx účinné xxxxx, xxxxx členský xxxx xxxxxxxx tuto stávající xxxxxxx xxxxx xx xxxxxxxxx x xxxxxx uvedených x xx. 5 xxxx. 2 xxxxxx xxxxxxxxxxx xxxx. b) xxxx x) xxxxxxxx (EU) x. 528/2012, xxxxx členský xxxx může předložit Xxxxxx xxxxxxxxxxx žádost x xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx členský stát xxxxxxxx xxxxxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxxxxxxx rejstříku. Xxxxx xxxxxx xxxxxxxx xxxxxxx informace, žádající xxxxxxx stát xxxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx.
3. Xxxxxxxx zveřejní žádost xxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxx státy nebo xxxx xxxxx xxxxx xxxxx xxxxxxxxxx ve lhůtě 60 xxx xx xxxxxxxxxx.
4. Xx xxxxxxx obdržených xxxxxxxxxx může Xxxxxx xxxxxxx xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 528/2012, xxxxx xxxxxx uvádět xxxxxxxx přípravky, jež xxxxxxxxx x xxxx xxxxx, xxxxxxxx xx xxxx x ní xxxxxxxx, na trh xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xx x xxxxx xxxxxxxx xxxxx x xxxxxxx x xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx x x xxxxxxxx xxxxxxxx xxxxxxxx 5 x xxxxxxxxx xxxxxxx xxxxxxxx uložených Xxxxxx.
5. Členský xxxx, xxxxx xx xxxxxxxx xxxxxxxx:
|
x) |
zajistí, že další xxxxxxxxx bude omezeno xx xxxxxx xxxxxxx a xxxxxxx xxxx, xxx xxxx plněny podmínky xxxxxxxx 1; |
|
x) |
xxxxxx xxxxxx opatření xx xxxxxxxx rizik, xxx xxxxxxxx minimalizaci expozice xxxxxxx, zvířat xxxx xxxxxxxxx xxxxxxxxx; |
|
x) |
xxxxxxx, aby xx xxxxxxx xxxxxxxxxxxx xxxxxx xxxx aby xxxx včas xxxx xxxxxxxxx platnosti odchylky xxxxxxxxxx xxxxxx o schválení xxxxxx xxxxx x xxxxxxx xxxxxxx 7 xxxxxxxx (XX) x. 528/2012. |
XXXXXXXX 5
ZÁVĚREČNÁ XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx se nařízení (XX) č. 1451/2007.
Xxxxxx xx zrušené xxxxxxxx xx xxxxxxxx za xxxxxx xx xxxx xxxxxxxx.
Xxxxxx 24
Vstup v xxxxxxxx
Xxxx nařízení xxxxxxxx x platnost xxxxxxxx xxxx xx xxxxxxxxx x Xxxxxxx věstníku Xxxxxxxx unie.
Xxxx xxxxxxxx je xxxxxxx v celém xxxxxxx x přímo xxxxxxxxxx xx xxxxx xxxxxxxxx státech.
X Xxxxxxx xxx 4. srpna 2014.
Xx Komisi
xxxxxxxx
Xxxx Manuel XXXXXXX
(1)&xxxx;&xxxx;Xx. xxxx. X 167, 27.6.2012, x. 1.
(2) Nařízení Xxxxxx (XX) x. 1451/2007 ze xxx 4. xxxxxxxx 2007 x druhé xxxxx xxxxxxxxxxxx pracovního xxxxxxxx xxxxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady 98/8/XX x xxxxxxx xxxxxxxxxx xxxxxxxxx na xxx (Xx. xxxx. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady 98/8/XX xx xxx 16. xxxxx 1998 o xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx (Xx. xxxx. X 123, 24.4.1998, x. 1).
(4) Rozsudek Soudního xxxxx (xxxxxxx senátu) ze xxx 1. března 2012 (xxxxxx x xxxxxxxxxx x předběžné xxxxxx: Landgericht Xxxxxxx – Německo) – Xöxx XxxX xxxxx Xxxxx GmbH (xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx – xxxxxxxx 98/8/XX – čl. 2 xxxx. 1 xxxx. x) – xxxxx „biocidní xxxxxxxxx“ – přípravek, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, aniž je xxxx, xxxxxxxx nebo xxxxxxxxxxx), X-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (XX) x.&xxxx;88/2014 ze xxx 31.&xxxx;xxxxx 2014, xxxxxx xx stanoví xxxxxx pro xxxxx xxxxxxx X&xxxx;xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (EU) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx na xxx x&xxxx;xxxxxx používání (Úř. xxxx. X 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. prosince 2008 x klasifikaci, xxxxxxxxxx a balení xxxxx x směsí, x xxxxx x xxxxxxx xxxxxxx 67/548/XXX x 1999/45/ES x x změně xxxxxxxx (XX) x. 1907/2006 (Xx. xxxx. X&xxxx;353, 31.12.2008, x. 1).
(7) Prováděcí nařízení Komise (XX) x.&xxxx;564/2013 xx xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx splatných Xxxxxxxx xxxxxxxx xxx xxxxxxxx látky podle xxxxxxxx Xxxxxxxxxx parlamentu x&xxxx;Xxxx (EU) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx trh a jejich xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, x. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 ze xxx 18. xxxxxxxx 2006 o xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx látek, x zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx xxxxxxxx 1999/45/XX a x zrušení xxxxxxxx Xxxx (XXX) x.&xxxx;793/93, xxxxxxxx Xxxxxx (ES) x. 1488/94, směrnice Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/ES x 2000/21/XX (Xx. věst. X 396, 30.12.2006, x. 1).
XXXXXXX X
Informace xxxxxxxxxx xxx xxxxxxxx podle xxxxxx 17
Xxxxxxxx xxxxx xxxxxx 17 xxxxxxxx xxxx xxxxxxxxx:
|
1) |
xxxxx, xx xxxxx xx xxxxxxxxx xxxxxxx xxxxxx xx xxxxxx xx. 3 xxxx. 1 xxxx. x) nařízení (XX) x. 528/2012; |
|
2) |
xxxxx x xxxx/xxxxxx xxxxxxxxx, xx xxxxx/x se xxxxxxxx xxxxxxxx; |
|
3) |
xxxxxxxxx o všech xxxxxxxx, xxxxx xxxx zadány xxx účely xxxxxxx x xxxxxxxxx či zařazení xx xxxxxxx I nařízení (EU) x. 528/2012, xxxxx x xxxxxxxxx xxxxx xxxxxx xxxxxxxxx; |
|
4) |
informace xxxxxxx x xxxxxxxx
|
|
5) |
xxxxx xxxx xxxx oznámení xxxxxxx v případě uvedeném x xx. 15 xxxx. x), xxxxx, xx xxxxx byla xx xxxx xxxx účinná xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxx x xxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxx pokynů xxxxxxxxx xx xxxxxxxx písmenu. |
XXXXXXX XX
KOMBINACE XXXXX X XXXX XXXXXXXXX XXXXXXXX XX XXXXXXXX XXXXXXXX DNE 4. XXXXX 2014
XXXX 1
Xxxxxxxxx xxxxxx xxxxx x xxxx přípravku xxxxxxxxxxx xx xxx 4. xxxxx 2014, s výjimkou xxxxxxxxxx jiných nanomateriálů xxx xxxx, které xxxx výslovně xxxxxxx x xxxxxxxxx 1017 x 1019.
|
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Xxxxxxx xxxx xxxxxxxxx |
Xxxxx XX |
Číslo CAS |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1 |
xxxxxxxxxxx |
XX |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
6 |
5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
|
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx mravenčí |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx salicylová |
NL |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
xxxxxx-1-xx |
XX |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
X |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
kyselina xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx xxxxxxxx |
LT |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
71 |
X-(+)-xxxxxx kyselina |
XX |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (xxxxxxx) |
UK |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
85 |
xxxxxxxxx |
XX |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
113 |
cinnamaldehyd/3-fenylprop-2-enal (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx kyselina (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (glutaraldehyd) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
154 |
xxxxxxxxx |
N |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
XX |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
oxid xxxxxxxx |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
180 |
(xxxxxxx-xxxxxxxxx) – natrium-dimethylarsinát |
XX |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
185 |
tosylchloramid, xxxxx xxx (xxxxx xxx xxxxxxxxxxxxxxx – xxxxxxxxx X) – (X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx |
ES |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
xxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
195 |
xxxxxxx-xxxxxxx-2-xxxx |
ES |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
198 |
X-[(xxxxxxxxxxxxxx)xxxxxxxx]xxxxxxxx (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
235 |
diuron |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (dazomet) |
BE |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
279 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X′,X′-xxxxxxxx-X-(4-xxxxxxxxxxx)xxxxxxxxxx (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
289 |
xxxxxxxxxxxx xxxxx |
FR |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx xxxxx/xxxxxx xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx měďný |
XX |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
315 |
xxxxx-2-xx-xxxxxxx |
XX |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
xxxxxxxxxxx |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
X-(3-xxxxxxxxxxx)-X-xxxxxxxxxxxxx-1,3-xxxxxx (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
XX |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
341 |
2-xxxxxxxxxxxxxxxxxxxxxxxxxx-3(2X)-xx (MIT) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
346 |
xxxxxxx-xxxxxxxxxxxxxxxxxx xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (XXX) |
XX |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
triklosan |
DK |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(ethylendioxy)dimethanol (xxxxxxx xxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxxxxxxxxx (XXXxxx)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
365 |
pyridin-2-thiol-1-oxid, xxxxx xxx (xxxxxxxxx xxxxx) |
SE |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
368 |
1-(3-chlorallyl)-3,5,7-triaza-1-azoniaadamantan-chlorid (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
382 |
1,3,4,6-tetrakis(hydroxymethyl)hexahydroimidazo[4,5-d]imidazol-2,5-dion (TMAD) |
ES |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
397 |
didecyldimethylamonium-chlorid (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
401 |
stříbro |
SE |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
403 |
měď |
FR |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
405 |
xxxx xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
XX |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
XX |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
DE |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
439 |
xxxxxxx xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
PL |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
450 |
xxxxxxxx stříbrný |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
peroxodisíran xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
XX |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
457 |
xxxxx |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
458 |
xxxxx xxxxxx |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
473 |
pyrethriny x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
491 |
oxid chloričitý |
PT |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
494 |
2,2-xxxxxx-2-xxxxxxxxxxxx (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
515 |
xxxxxx amonný |
XX |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
522 |
zink-1-oxo-1λ5-pyridin-2-thiolát |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
|
524 |
xxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxx |
ES |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
|
526 |
kalium-bifenyl-2-olát |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
|
529 |
brommonochlorid |
NL |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
531 |
(xxxxxxxxx)xxxxxxxx |
XX |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx xxxxxxx (xxxxxxxxx mědi) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (XXXX) |
XX |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
559 |
[(xxxxxxxxxxxx-2-xx)xxxxxxxx]xxxxxx-xxxxxxxxxx (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
563 |
xxxxxx-(X,X)-xxxx-2,4-xxxxxxx (xxxxxx xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
571 |
2-oktyltetrahydroisothiazol-3-on (OIT) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
577 |
dimethyl(oktadecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
ES |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
578 |
N2-terc-butyl-N4-cyklopropyl-6-(methylsulfanyl)-1,3,5-triazin-2,4-diamin (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX/xxxxxxxxxxxxxxxxxxxxxxxxxx) |
NL |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
590 |
3-(4-xxxxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx/xxxxxxxxxxx |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
597 |
1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxx) |
DE |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
X-[(6-xxxxx-2-xxxxxxxxxx[4,5-x]xxxxxxx-3(2X)-xx)xxxxxx]-X,X-xxxxxxxx-xxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
961 |
oxid xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx dolomitické xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (cyfenothrin) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
608 |
xxxxxxxx(xxxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
609 |
xxx- x xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (xxxxxxxxxx) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
614 |
(XX)-α-xxxxx-3-xxxxxxxxxxxx-(1XX)-xxx,xxxxx-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
618 |
[1-xxxxxxx-2-xxxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (empenthrin) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
619 |
3-jodprop-2-yn-1-yl-N-butylkarbamát (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
635 |
alkyltrimethylammoniumchlorid xxxxxxxxxx xxxxx (XXXXX/XXXX) |
IT |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
648 |
4,5-xxxxxxx-2-xxxxxxxxxxxxxxx-3(2X)-xx (4,5-dichlor- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
656 |
xxx(5-xxxxxxxxxxxxxxxx-3-xx)xxxxxx (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxxx) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
666 |
[(3-fenoxy-4-fluorfenyl)kyanmethyl]-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropan-1-karboxylát (cyfluthrin) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
667 |
xxxxx(X12-18)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (C12-18)) |
XX |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
671 |
alkyl(C12-16)dimethylbenzylammoniumchlorid (ADBAC/BKC (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (DDAC) (X8-10) |
IT |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (MMPP) |
PL |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
margosa, Xxxxxxxxxxx xxxxxx, výtažek |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-X14)) |
IT |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
725 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXXX (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
731 |
xxxxxxxxx xxxxxxxxxxxx, Chrysanthemum xxxxxxxxxxxxxxxx, xxxxxxx |
XX |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
744 |
xxxxxxxxx xxxxxx, Xxxxxxxxx xxxxxxx, výtažek/levandulový xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxxxxxx) |
XX |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
779 |
xxxxxxx xxxxxxxx xxxxxxxxx kyseliny a X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (xxxxxxxxxxxxx) |
DE |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (BBIT) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
792 |
xxxxxxx xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
XX |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (xxxxxxxx) |
XX |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
797 |
1-((Z)-3-chlorallyl)-3,5,7-triaza-1-azoniaadamantanchlorid (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-karboxylát (xxxx xxxxxxxxxxxxx) (xxxxxxxxxxx) |
XX |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
790 |
5-xxxxx-2-(4-xxxxxxxxxxx)xxxxx (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (chlothianidin) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
952 |
Xxxxxxxx sphaericus 2362, kmen XXXX-1743 |
XX |
xxxxxxxxxxxxxxx |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. xxxxxxxxxxx, xxxx XX3X |
XX |
mikroorganismus |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
957 |
Xxxxxxxx xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx relevantní |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 247-500-7) x 2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 220-239-6), směs (3:1) (směs XXXX/XXX) |
XX |
směs |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
939 |
aktivní xxxxx (xxxxxxxx xxxxxx xxxxxxxx chlorné x xxxxxxxxx xxxxxxx xx xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
peroxyoktanová xxxxxxxx |
XX |
není xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
není relevantní |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
931 |
xxxxxxxxxxxxxxxxxxxxxxx, X-X12-14(xx xxxxx číslem), xxxxxxxx reakce x xxxxxxxxxxxx kyselinou (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
produkty xxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxx a chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx xxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxx |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
777 |
reakční xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx s chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
810 |
xxxxxxxxxxxxxx xxxx x xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
824 |
xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
SE |
xxxx x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx na xxxxx xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx xxxxxxxxxx agregátu x primárními xxxxxxxxx xx xxxxxxxxxx) |
SE |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (xxxx xxxxxxxxxxxx tvořený xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx k dispozici |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
831 |
xxxxxxxxx |
XX |
přípravek na xxxxxxx rostlin |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (xxxx 4 izomerů 1R xxxxx, 1X: 1X xxxxx, 1X: 1X xxx, 1X: 1X xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxx 2 xxxxxxxxxxxxx) (xxxxxxxxxx) |
DE |
přípravek na xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (acetamiprid) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
835 |
xxxxxxxxxxxx/(X)-(3-xxxxxxxxxxx)xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
BE |
xxxxxxxxx xx xxxxxxx rostlin |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (xxxxxxxxxxxx) |
PT |
přípravek xx xxxxxxx rostlin |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
859 |
xxxxxxx X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) x (xxxxxxxxxxx)xxxxxxxx (XXXXXX 203-439-8)/xxxxxxxxx xxxxxxxxx chlorid xxxxxx (XX Xxxxxxx) |
XX |
xxxxxxx |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
863 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx) (XXXX) |
XX |
xxxxxxx |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
FR |
xxxxxxx |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
869 |
α-[2-(xxxxxxxxxxxxxxxxxxx)xxxxx]-ω-[xxxxxxxxxxx(xxxxxxxxxx)-xxxxxxxxx] (Xxxxxx 26) |
IT |
polymer |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx xxxxxx) |
EL |
polymer |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx nepodporované xx xxx 4. xxxxx 2014
Tato xxxx xxxx xxxxxxx obsahuje
|
— |
kombinace xxxxx x xxxx přípravku xxxxxxx x xxxxxxx níže, xxxxxx xxxxxxxxxx xxxxxxxxx, |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx a typu přípravku xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, xxxxx xxxx xxxxxxx x xxxxxxx, x |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxx přípravku xxxxxxxxxxx xx 4. srpna 2014, x xxxxxxxx xxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx. |
Kombinace xxxxx a typu přípravku x nanomateriály xxxxxxxx xx xxxx xxxxx xxxxx xxxxxxxxx rozhodnutí x neschválení xxxxx xxxxxx 20, xxxxxxxx xxxxx osoba xxxxxx xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxx v platnost xxxxx xx. 14 xxxx. 3 xxxx xxxxx xx takové xxxxxxxx xxxxxxxxx xxxxx xx. 17 odst. 4 nebo 5.
|
Xxxxx položky |
Název xxxxx |
Xxxxxxx xxxx zpravodaj |
Xxxxx XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx definovaný xxxxx xxxxxxx 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
166 |
benzyl(hexadecyl)dimethylamonium-chlorid (xxx xxxxxxx 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
benzyl(dimethyl)oktadecylamonium-chlorid (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
benzyl(dimethyl)tetradecylamonium-chlorid (xxx xxxxxxx 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx položka 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
418 |
xxxx křemičitý xxxxxxx |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
449 |
xxxxx xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
XX |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
xxxxx(xxxxxxxx)xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
xxxxxxxxxxxxxx(xxxxxxx-9-xx-1-xx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-fenoxybenzyl(1RS,3RS;1RS,3SR)-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropankarboxylát (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
637 |
alkyl(benzyl)dimethylamonium-chloridy (xxxxx odvozen od xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxx xxxxxxx 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx odvozen xx mastných kyselin xxxxxxxxxx xxxxx) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx hydrogenovaných xxxxxxxx xxxxxxx xxxx) (xxx xxxxxxx 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
xxxxxxx(X6-X12)xxxxxxxxxxxxxxx-xxxxxxxx (xxx položka 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
alkyl(C8-C16)benzyl(dimethyl)amonium-chloridy (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
alkyl(C10-C16)dimethylaminoxidy |
PT |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
dialkyl(C8-C18)dimetylamonium-chloridy (xxx xxxxxxx 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx jiný xxx x xxxxx xxxxxxxx Xxxxxxxxxxx indica xxxxxxxxxxx vodou x xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx xxxxxxxxxx xxxxx položky 777) |
NL |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
778 |
1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-[(1X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxx-3-xx (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx xxxxxxx dimethyl-adipátu, xxxxxxxx-xxxxxxxxx x xxxxxxxx-xxxxxxxxx x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X6-X18) xxxxxxxx x xxxxxxxxxx, xxxxxxxx od xxxxxxxx kyselin loje, xxxxxxxxxx xxxxx x xxxxxxxx xxxxx) (XXXX) |
IT |
směs xxxxx uvedených v xxxxxxx XXXXXX |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -methyl-sulfáty) (xxxxxx (X8-X18) nasycené x nenasycené, xxxxxxxx xx xxxxxxxx xxxxxxx xxxx, kokosového oleje x xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -xxxxxxxxx) (alkyly (X8-X22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx xxxxxxx loje, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXX) |
XX |
xxxx xxxxx uvedených x xxxxxxx XXXXXX |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
1001 |
xxxxx(X12-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx než látka xxxxxxxxx xxx xxxxxxx 671) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
|
1002 |
alkyl(C12-C18)benzyl(dimethyl)amonium-chloridy(jiné xxx látka spadající xxx xxxxxxx 667) |
XX |
není xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- chloridy (xxxx xxx xxxxx xxxxxxxxx pod položku 725) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1005 |
xxxxx(X12-X14)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 724) |
XX |
xxxx xxxxxxxxxx |
není relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1006 |
xxxxxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx, hliník x xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1009 |
xxxxxxx(X8-X10)xxxxxxxxxxxxxx-xxxxxxxx (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 673) |
IT |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
1011 |
alkyl(trimethyl)amonium-chloridy (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxxx než látka xxxxxxxxx xxx xxxxxxx 635) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
1012 |
xxxxxxxxxxxxxxxxx xxxxx, xxxxxxxx x xxxxxxxxx xxxxxxx/xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
není xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx technický) |
DE |
přípravek xx xxxxxxx rostlin |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
|
Xxxx přípravků |
Xxxxx xxx xxxxxxxxxx hodnotící xxxxxx xxxxx xx. 6 xxxx. 3 xxxx. x) |
Xxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 7 odst. 2 písm. b) |
|
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
|
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
|
1 x 2 |
31.12.2018 |
31.3.2019 |
|
6 x 13 |
31.12.2019 |
31.3.2020 |
|
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
|
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |